The pluralization of the international: Resistance and alter-standardization in regenerative stem cell medicine

Social Studies of Science

Volumn 46, Issue 1, 2016, Pages 112-139

  Rosemann, Achim ^a   Chaisinthop, Nattaka ^b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

clinical trials; evidence based medicine; regenerative stem cell medicine; standardization; technology regulation

Indexed keywords

DEVELOPED COUNTRY; DEVELOPING COUNTRY; GOVERNMENT REGULATION; POLITICS; REGENERATIVE MEDICINE; STANDARDS; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; GOVERNMENT REGULATION; POLITICS; REGENERATIVE MEDICINE; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION;

EID: 84957866032     PISSN: 03063127     EISSN: 14603659     Source Type: Journal    
DOI: 10.1177/0306312715619783     Document Type: Article

References (96)

1. T.Ackerman (2012) Texas accused of ignoring FDA on stem cell rules. Center for Genetics and Society. Available at: http://www.geneticsandsociety.org/article.php?id=6160 (accessed 4 November 2015).
2. M.Baker (2005) Stem cell therapy or snake oil?Nature Biotechnology23(12): 1467–1469.
3. S.Barrett (2012) Court enjoins stem cell treatment. Quackwatch. Available at: http://www.quackwatch.org/02ConsumerProtection/FDAActions/regenexx/overview.html (accessed 4 November 2015).
4. B.Bedell (2012) Why can’t we use our own stem cells to heal our bodies?Foundation for Alternative and Integrative Medicine. Available at: http://www.faim.org/stemcell/why-cant-we-use-our-own-stem-cells-heal-our-bodies.html (accessed 4 November 2015).
5. P.BiancoD.Sipp (2014) Sell help not hope. Nature510(7505): 336–337.
6. A.Blasimme (2013) Translating stem cells to the clinic: Scientific societies and the making of regenerative medecine. Quaderni81: 29–44.
7. S.Blume (2010) The Artificial Ear: Cochlear Implants and the Culture of Deafness. New Brunswick, NJ and London: Rutgers University Press.
8. A.CambrosioP.KeatingT.SchlichG.Weisz. (2009) Biomedical conventions and regulatory objectivity: A few introductory remarks. Social Studies of Science39(5): 651–664.
9. CCTV (2002) Hope for the cure of spinal cord injury. Central Chinese television: The Healthy Way [Jiangkang Zhilu]. Central Chinese Television, Channel 10, 4. Available at: http://www.cctv.com/life/jiankangzhilu/index020204.html (accessed 4 November 2015).
10. L.ChenD.ChenH.XiQ.WangY.Liu. (2012) Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateral sclerosis patients: Benefits from multiple transplantations. Cell Transplantation21(Suppl. 1): S65–S77.
11. L.ChenH.HuangH.XiZ.XieR.Liu. (2010) Intracranial transplant of olfactory ensheathing cells in children and adolescents with cerebral palsy: A randomized controlled clinical trial. Cell Transplantation19(2): 185–191.
12. L.ChenZ.JiangH.HuangH.XiQ.Wang. (2011) Strategy of pain neurorestoratology for chronic pain by cell transplantation: 8 cases report. China Medical Herald4: 24.
13. L.ChenA.SharmaJ.GuoD.MuresanuH.Huang. (2013a) Annual advances in neurorestoratology: A summary of IANR VI and 10th GCNN conference, Bucharest, Romania, April 4-7, 2013. CNS & Neurological Disorders-Drug Targets12(5): 547–549.
14. L.ChenH.XiH.HuangY.LiuD.Chen. (2013b) Multiple cell transplantation based on an intraparenchymal approach for patients with chronic phase stroke. Cell Transplantation22(Suppl. 1): S83–S91.
15. Chinese Branch of IANR (2013) Standard recommendations for the application of Chinese clinical cell therapy for neurorestoration. Cell Transplantation22(Suppl. 1): S5–S10.
16. M.Cooper (2008) Life as Surplus: Biotechnology and Capitalism in the Neoliberal Era. Seattle, WA and London: University of Washington Press.
17. M.CooperC.Waldby (2014) Clinical Labor: Tissue Donors and Research Subjects in the Global Bioeconomy. Durham, NC and London: Duke University Press.
18. D.Cyranoski (2006) Patients warned about unproven spinal surgery. Nature440(7086): 850–851.
19. D.Cyranoski (2009) Stem-cell therapy faces more scrutiny in China: But regulations remain unclear for companies that supply treatments. Nature459(7244): 146–147.
20. D.Cyranoski (2010) FDA challenges stem cell clinic. Nature466(7309): 909.
21. D.Cyranoski (2012a) Editor’s move sparks backlash. Nature482(7386): 449–450.
22. D.Cyranoski (2012b) Stem cell therapy takes off in Texas. Nature483(7387): 13–14.
23. D.Cyranoski (2013) Japan to offer fast-track approval path for stem cell therapies. Nature Medicine19(5): 510.
24. J.J.DarrowA.SarpatwariJ.AvornA.S.Kesselheim. (2015) Practical, legal, and ethical issues in expanded access to investigational drugs. The New England Journal of Medicine372(3): 279–286.
25. B.H.DobkinsA.CurtJ.Guest (2006) Cellular transplants in China: Observational study from the largest human experiment in chronic spinal cord injury. Neurorehabilitation and Neural Repair20(1): 5–13.
26. E.Dolgin (2010) Survey details stem cell clinics ahead of regulatory approval. Nature Medicine16(5): 495.
27. R.Epstein (2013) The FDA’s Misguided Regulation of Stem-Cell Procedures: How Administrative Overreach Blocks Medical Innovation (Report). The Manhattan Institute for Policy Research. Available at: http://www.manhattan-institute.org/html/lpr_17.htm#.U0XHCZjZiwI (accessed 4 November 2015).
28. S.Epstein (1996) Impure Science: AIDS, Activism, and the Politics of Knowledge. Berkeley, CA: University of California Press.
29. A.Faulkner (2012) Law’s performativities: Shaping the emergence of regenerative medicine through European Union legislation. Social Studies of Science42(5): 753–774.
30. A.Faulkner (2014) Special treatment? Exceptions and exemptions in the politics of regenerative medicine gatekeeping in the UK in global context. Presented at Global Life Sciences and Bionetworking: Cell Therapy Production, Provision and Policies, University of Sussex, Brighton, 12November.
31. FDA (2012) FDA Inspector’s Report of ICMS IRB. International Cellular Medicine Society. Available at: http://www.cellmedicinesociety.org/attachments/415_FDA%20483%20-%20ICMS%20IRB%20-%2019%20June%202012%20(redacted).pdf (accessed 4 November 2015).
32. B.Hanson (2010) ICMS offshore guide is far more practical than the ISSCR’s idea of world regulation. Available at: http://www.stemcellpioneers.com/archive/index.php/t-3000.html (accessed 4 November 2015).
33. L.F.Hogle (2014) Contemporary issues in regenerative medicine research ethics and governance: An overview. In: (ed.) Regenerative Medicine Ethics: Governing Research and Knowledge Practices. New York: Springer, 3–28.
34. H.Huang (2010) Neurorestoratology, a distinct discipline and a new era: A brief introduction to the first IANR section. Cell Transplantation19(2): 129–131.
35. H.Huang (2013) Progress in cellular neurorestoratology: A brief introduction to the IANR supplement issue. Cell Transplantation22(Suppl. 1): S1–S3.
36. H.HuangL.ChenP.R.Sanberg (2010) Cell therapy from bench to bedside translation in CNS neurorestoratology era. Cell Medicine: Part B of Cell Transplantation1(1): 15–46.
37. H.HuangL.ChenP.R.Sanberg (2012) Clinical achievements, obstacles, falsehoods, and future directions of cell-based neurorestoratology. Cell Transplantation21(Suppl. 1): S3–S11.
38. H.HuangL.ChenH.XiH.WangJ.Zhang. (2008) Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: A controlled pilot study. Clinical Transplantation22(6): 710–718.
39. H.HuangL.ChenH.XiQ.WangJ.Zhang. (2009) Olfactory ensheathing cells transplantation for central nervous system diseases in 1255 patients. Zhongguo Xiufu Chongjian Waike Zazhi [Chinese Journal of Surgical Repair and Reconstruction] 23(1): 14–20.
40. H.HuangH.WangL.ChenZ.GuJ.Zhang. (2006) Influence factors for functional improvement after olfactory ensheathing cell transplantation for chronic spinal cord injury. Zhongguo Xiufu Chongjian Waike Zazhi [Chinese Journal of Surgical Repair and Reconstruction] 20(4): 434–438.
41. I.Hyun (2010) Allowing room for innovative stem cell-Based therapies outside clinical trials: Ethical and practical challenges. Journal of Law, Medicine, and Ethics38(2): 277–285.
42. International Association of Neurorestoratology (IANR) (2009) Beijing Declaration of International Association of Neurorestoratology. Cell Transplantation18(4): 487.
43. International Association of Neurorestoratology (IANR) (2010) Introduction. IANR. Available at: http://ianr.org.cn/english/ (accessed 4 November 2015).
44. International Association of Neurorestoratology (IANR) (2011) IANR IV and 8th GCNN conference, Amman, Jordan, 27–30April. IANR. Available at: http://ianr.org.cn/pdf/Abstract%20Summaries%20of%20IANR%20IV%20and%208th%20GCNN%20Conference.pdf (accessed 4 November 2015).
45. International Cellular Medicine Society (ICMS) (2010a) Clinical Translation of Adult Stem Cell Lines. ICMS. Available at: http://www.cellmedicinesociety.org/attachments/382_Clinical%20Translation%20of%20Adult%20Stem%20Cells.pdf (accessed 4 November 2015).
46. International Cellular Medicine Society (ICMS) (2010b) The ICMS Open Treatment Registry. ICMS. Available at: http://www.cellmedicinesociety.org/attachments/184_ICMS%20Open%20Treatment%20Registry%20-%20Overview.pdf (accessed 4 November 2015).
47. International Society for Stem Cell Research (ISSCR) (2008) ISSCR Guidelines for the Clinical Translation of Stem Cells. ISSCR. Available at: http://www.isscr.org/docs/guidelines/isscrglclinicaltrans.pdf (accessed 4 November 2015).
48. P.KeatingA.Cambrosio (2011) Cancer on Trial: Oncology as a New Style of Practice. Chicago, IL and London: Chicago University Press.
49. S.KiatpongsanD.Sipp (2008) Offshore stem cell treatments. Nature Reports Stem Cells10: 1038.
50. P.S.Knoepfler (2012a) ICMS President Rodriguez Interview on Adult Stem Cell Regulatory Issues. The Niche: Knoepfler Lab Stem Cell Blog. Available at: https://www.ipscell.com/2012/05/icms-president-rodriguez-interview-on-adult-stem-cell-regulatory-issues/ (accessed 4 November 2015).
51. P.S.Knoepfler (2012b) Interviews with Centeno and Sipp on Key Case on FDA Authority over Stem Cells. The Niche: Knoepfler Lab Stem Cell Blog. Available at: http://www.ipscell.com/2012/05/interviews-with-centeno-and-sipp-on-key-case-on-fda-authority-over-stem-cells/(accessed 4 November 2015).
52. P.S.Knoepfler (2012c) Intriguing reading as ICMS posts 483 report of FDA audit: Still awaiting news on Celltex. Available at: http://www.allreadable.com/d215BdkQ (accessed 4 November 2015).
53. P.S.Knoepfler (2012d) Recommendations to ICMS for improved practices. Available at: http://www.ipscell.com/2012/05/recommendations-to-icms-for-improved-practices/ (accessed 4 November 2015).
54. P.S.Knoepfler (2012e) Studio Sacramento: The promise of stem cell research. Available at: https://www.youtube.com/watch?t=30&v=9QfT-kvwQPs (accessed 4 November 2015).
55. P.S.Knoepfler (2013) Cell surgical network series Part 3: Opinion piece on key concerns. Available at: http://www.ipscell.com/2013/11/cell-surgical-network-series-part-3-opinion-piece-on-key-concerns/ (accessed 15 April 2015).
56. G.Koleva (2012) Stem cells and the lawsuit that may shape our medical future. Forbes, 10February. Available at: http://www.forbes.com/sites/gerganakoleva/2012/02/10/stem-cells-and-the-lawsuit-that-may-shape-our-medical-future/ (accessed 8 December 2015).
57. O.LindvallI.Hyun (2009) Medical innovation versus stem cell tourism. Science324(5935): 1664–1665.
58. T.Lysaght (2014) Cellular therapies: Regulating uncertainty in Asia’s biomedical hubs. Asian Bioethics Review6(3): 234–245.
59. D.S.McMahon (2014) The global industry for unproven stem cell interventions and stem cell tourism. Tissue Engineering and Regenerative Medicine11(1): 1–9.
60. B.MaddenG.Conko (2013) Free to Choose Medicine. The Federalist Society for Law and Public Policy Studies. Available at: http://www.fed-soc.org/publications/detail/free-to-choose-medicine (accessed 4 November 2015).
61. M.A.Malarkey (2008) Untitled letter. Available at: http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/complianceactivities/enforcement/untitledletters/ucm091991.htm (accessed 4 November 2015).
62. K.MartellA.TrounsonE.Baum (2010) Stem cell therapies in clinical trials: Workshop on best practices and the need for harmonization. Cell Stem Cell7(4): 451–454.
63. G.H.Morgan (2014) H.R.4475: Compassionate Freedom of Choice Act of 2014. Congress.gov. Available at: https://www.congress.gov/bill/113th-congress/house-bill/4475 (accessed 4 November 2015).
64. E.MykhalovskiyL.Weir (2004) The problem of evidence-based medicine: Directions for social science. Social Science & Medicine59: 1059–1069.
65. Nanfang Zhoumo [Southern Weekend] (2006) Huang Hongyun: Striking breakthrough or science bubble. Nanfang Zhoumo [Southern Weekend], 21July. Available at: http://www.bioon.com/biology/chinese/185809.shtml (accessed 4 November 2015).
66. A.Petryna (2009) When Experiments Travel: Clinical Trials and the Global Search for Human Subjects. Princeton, NJ: Princeton University Press.
67. J.PettyC.A.Heimer (2011) Extending the rails: How research reshapes clinics. Social Studies of Science41(3): 337–360.
68. K.S.Rajan (2010) The experimental machinery of global clinical trials: Case studies from India. In: (eds) Asian Biotech: Ethics and Communities of Fate. Durham and London: Duke University Press, pp. 55–80.
69. R.L.Rodriguez (2012) ICMS President Rodriguez Interview on Adult Stem Cell Regulatory Issues. The Niche: Knoepfler Lab Stem Cell Blog. Available at: http://www.ipscell.com/2012/05/icms-president-rodriguez-interview-on-adult-stem-cell-regulatory-issues/ (accessed 4 November 2015).
70. A.Rosemann (2013) Medical innovation and national experimental pluralism: Insights from clinical stem cell research and applications in China. BioSocieties8(1): 58–74.
71. S.Rudavsky (2015) Legislation would allow ‘right-to-try’ trial drugs. USA Today, 2February. Available at: http://www.usatoday.com/story/news/nation/2015/02/03/legislation-would-allow-right-to-try-experimental-drugs/22821457/ (accessed 4 November 2015).
72. A.SharmaN.Gokulchandran (2009) Stem Cell Therapy in Neurological Disorders. NeuroGen Brain and Spine Institute. Available at: http://issuu.com/neurogenbsi/docs/book_final (accessed 4 November 2015).
73. A.SharmaP.BadheN.GokulchandranG.ChopraM.Lohia. (2011) Stem Cell Therapy & Other Recent Advances in Muscular Dystrophy. NeuroGen Brain and Spine Institute. Available at: http://www.neurogen.in/pdfs/books/Muscular%20Dystrophy%20Book.pdf (accessed 4 November 2015).
74. A.SharmaP.BadheN.GokulchandranP.KulkarniP.Mishra. (2013a) An improved case of autism as revealed by PET CT Scan in patient transplanted with autologous bone marrow derived mononuclear cells. Journal of Stem Cell Research and Therapy3(2): 139.
75. A.SharmaN.GokulchandranG.ChopraP.KulkarniM.Lohia. (2012) Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life. Cell Transplantation21(Suppl. 1): S79–S90.
76. A.SharmaN.GokulchandranH.SaneA.NagrajanA.Paranjape. (2013b) Autologous bone marrow mononuclear cell therapy for autism: An open label proof of concept study. Stem Cells International2013(2013): 623875.
77. A.SharmaN.GokulchandranH.SaneP.BadheP.Kulkarni. (2013c) Detailed analysis of the clinical effects of cell therapy for thoracolumbar spinal cord injury: An original study. Journal of Neurorestoratology1: 13–22.
78. A.SharmaN.GokulchandranH.SaneP.KulkarniN.Thomas. (2013d) Intrathecal autologous bone marrow mononuclear cell transplantation in a case of adult autism. Autism3(2): 113.
79. A.SharmaA.ParanjapeH.SaneK.BhagawananiN.Gokulchandran. (2013e) Cellular transplantation alters the disease progression in Becker’s muscular dystrophy. Case Reports in Transplantation2013(2013): 909328.
80. A.SharmaH.SaneD.KhopkarN.GokulchandranV.C.Jacob. (2014a) Functional recovery in chronic stage of spinal cord injury by neurorestorative approach: A case report. Case Reports in Surgery2014(2014): 404207.
81. A.SharmaH.SaneA.NagrajanN.GokulchandranP.Badhe. (2014b) Autologous bone marrow mononuclear cells in ischemic cerebrovascular accident paves way for neurorestoration: A case report. Case Reports in Medicine2014(2014): 530239.
82. D.Sipp (2014) The domestication of stem cell tourism. In: (eds) Routledge Handbook of Medical Law and Ethics. London and New York: Routledge, pp. 443–455.
83. M.Sleeboom-Faulkner (2013) Latent science collaboration: Strategies of bioethical capacity building in Mainland China’s stem cell world. BioSocieties8(1): 7–24.
84. M.Sleeboom-Faulkner (2014) Global life sciences and bionetworking: Cell therapy production, provision and policies. Available at: https://www.youtube.com/watch?v=wce3E-fELtU (accessed 4 November 2015).
85. M.Sleeboom-FaulknerA.RosemannK.Patra. (under review) National home-keeping and the regulation of stem cell research and cell therapy: An international perspective. Social Science and Medicine.
86. M.Sleeboom-FaulknerP.K.Patra (2011) Experimental stem cell therapy: Biohierarchies and bionetworking in Japan and India. Social Studies of Science41(5): 645–666.
87. S.Sternberg (2011) Doctors offer unapproved stem cell therapies. USA Today, 26June. Available at: http://usatoday30.usatoday.com/news/health/story/health/story/2011/06/Doctors-offer-unapproved-stemcell-therapies/48933666/1 (accessed 4 November 2015).
88. L.Thévenot (2009) Governing life by standards: A view from engagements. Social Studies of Science39(5): 793–813.
89. C.Thompson (2010) Asian Regeneration? Nationalism and internationalism in Stem Cell Research in South Korea and Singapore. In: (eds). Asian Biotech: Ethics and Communities of Fate. Durham, NC and London: Duke University Press, pp. 95–117.
90. S.TimmermansM.Berg (2003) The Gold Standard: The Challenge of Evidence-Based Medicine and Standardization in Health Care. Philadelphia, PA: Temple University Press.
91. S.TimmermansS.Epstein (2010) A world of standards but not a standard world: Toward a sociology of standards and standardization. Annual Review of Sociology36: 69–89.
92. P.Van ZwanenbergA.ElyA.Smith (2011) Regulating Technology: International Harmonization and Local Realities. London: Routledge.
93. S.ViswanathanM.RaoA.KeatingA.Srivastava (2013) Overcoming challenges to initiating cell therapy clinical trials in rapidly developing countries: India as a model. Stem Cells Translational Medicine2(8): 607–613.
94. D.Y.Wohn (2012) Korea okays stem cell therapies despite limited peer-reviewed data. Nature Medicine18(3): 329.
95. H.XiL.ChenH.HuangF.ZhangY.Liu. (2013) Preliminary report of multiple cell therapy for patients with multiple system atrophy. Cell Transplantation22(Suppl. 1): S93–S99.
96. J.Ziegler (2013) When ‘no option’ is not an acceptable option. CellR4. Available at: http://www.cellr4.org/article/390 (accessed 4 November 2015).